Phase II Trial of SMO/AKT/NF2 inhibitors in Progressive Meningioma’s with SMO/AKT/NFT2 Mutations.

 

Coordinator’s Contact Info:

Mayra/Lisandra
305-519-2147
MSMC ONLY